Zacks Investment Research upgraded shares of Innovus Pharmaceuticals Inc (NASDAQ:INNV) from a sell rating to a hold rating in a research note released on Tuesday.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Shares of Innovus Pharmaceuticals (NASDAQ INNV) traded up 4.3636% during trading on Tuesday, hitting $0.1148. The company had a trading volume of 137,090 shares. The firm’s market capitalization is $17.28 million. Innovus Pharmaceuticals has a 52-week low of $0.08 and a 52-week high of $0.59. The stock’s 50-day moving average is $0.12 and its 200 day moving average is $0.14.

COPYRIGHT VIOLATION WARNING: “Innovus Pharmaceuticals Inc (NASDAQ:INNV) Stock Rating Upgraded by Zacks Investment Research” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Innovus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.